Floatz logo

DOTATOC

Carcinoid Tumors

Sue O'Dorisioprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Carcinoid Tumors cohort.

Asset / SponsorPhaseRating
Paltusotine
Crinetics Pharmaceuticals Inc.
Phase 3BB
Oxodotreotide
RayzeBio, Inc.
Phase 3BB
Everolimus
RayzeBio, Inc.
Phase 3B
Lanreotide
RayzeBio, Inc.
Phase 3B
Octreotide Pamoate
RayzeBio, Inc.
Phase 3B

View all 30 →

Same molecule, other indications

DOTATOC is also rated in:

digestive system neuroendocrine neoplasmDormant
B
Indicative ·
63 / 100
View asset →
neuroblastomaDormant
B
Indicative ·
60 / 100
View asset →
carcinoid tumorDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →